HLS Therapeutics (TSE:HLS) Stock Price Down 7.4% – Time to Sell?

HLS Therapeutics Inc. (TSE:HLS)’s share price dropped 7.4% during mid-day trading on Thursday. The stock traded as low as C$3.75 and last traded at C$3.89. 388,910 shares changed hands during trading, an increase of 1,077% from the average daily volume of 33,030 shares. The stock had previously closed at C$4.20.

Analysts Set New Price Targets

A number of research firms recently issued reports on HLS. Canaccord Genuity Group upgraded shares of HLS Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 13th. Raymond James Financial raised shares of HLS Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the company from C$7.00 to C$8.00 in a research note on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Strong Buy” and a consensus price target of C$8.00.

HLS Therapeutics Trading Down 0.5%

The company has a current ratio of 1.05, a quick ratio of 1.01 and a debt-to-equity ratio of 75.86. The firm has a market cap of C$119.72 million, a PE ratio of -14.33 and a beta of -0.48. The firm has a fifty day simple moving average of C$3.93 and a two-hundred day simple moving average of C$4.26.

HLS Therapeutics (TSE:HLS) last posted its quarterly earnings data on Wednesday, August 12th. The company reported C($0.03) earnings per share (EPS) for the quarter. The firm had revenue of C$14.67 million during the quarter. HLS Therapeutics had a negative return on equity of 14.39% and a negative net margin of 15.26%.During the same period last year, the business posted ($0.09) EPS. Equities analysts forecast that HLS Therapeutics Inc. will post -0.12 EPS for the current year.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.